Corticosteroid Side Effects and Management
Systemic corticosteroids cause multiple organ system toxicities that require proactive baseline risk assessment, patient education, and structured monitoring—particularly for osteoporosis, hyperglycemia, hypertension, infections, and psychiatric disturbances.
Common Side Effects by Frequency
The most frequent adverse events occur across multiple organ systems 1:
Cardiovascular (15 per 100 patient-years)
- Hypertension (prevalence >30%)
- Dyslipidemia
- Peripheral edema
- Water and electrolyte imbalance
- Increased cardiovascular disease risk
Infectious Complications (15 per 100 patient-years)
- Viral, bacterial, and skin infections
- Increased susceptibility to opportunistic infections
- Critical warning: Chickenpox exposure can be life-threatening in patients on chronic corticosteroids
Gastrointestinal (10 per 100 patient-years)
- Peptic ulcer disease (particularly costly at $21,825 per year)
- Pancreatitis
- Gastrointestinal bleeding risk increases substantially with concurrent NSAID use
Neuropsychiatric (9 per 100 patient-years)
- Minor mood disturbances to severe steroid psychosis
- Depression, mania, anxiety
- Cognitive deficits
- Incidence ranges 5-20% depending on dose and duration 2
Endocrine and Metabolic (7 per 100 patient-years)
- Glucose intolerance and diabetes (4-fold increased risk vs. controls) 3
- Fat redistribution (Cushingoid features)
- Adrenal suppression and insufficiency
- Weight gain
Dermatological (5 per 100 patient-years)
- Cutaneous atrophy
- Acne, hirsutism, alopecia
- Easy bruising
Musculoskeletal (4 per 100 patient-years)
- Osteoporosis and fractures (21-30% prevalence)
- Osteonecrosis
- Myopathy
Ophthalmologic (4 per 100 patient-years)
- Cataracts (1-3% prevalence)
- Glaucoma
Mandatory Pre-Treatment Assessment
Before initiating corticosteroids, evaluate and document the following risk factors 1:
- Hypertension
- Diabetes or glucose intolerance
- History of peptic ulcer disease
- Recent fractures or osteoporosis
- Presence of cataract or glaucoma
- Active or chronic infections
- Dyslipidemia
- Concurrent NSAID use
- Psychiatric history
- Pregnancy status
Required Patient Education
Discuss adverse effects with every patient before starting therapy and provide written information 1:
- Never stop corticosteroids abruptly (adrenal crisis risk)
- Seek immediate care if exposed to chickenpox or become acutely ill
- Increased infection susceptibility
- Carry a steroid treatment card documenting dose, start date, and tapering schedule
- Show this card to all healthcare providers
Structured Monitoring Protocol
During Active Treatment 1
Monitor the following parameters at intervals based on dose and duration:
- Body weight (each visit)
- Blood pressure (each visit)
- Peripheral edema (each visit)
- Fasting blood glucose or HbA1c (baseline, then every 3-6 months)
- Serum lipids (baseline, then every 6-12 months)
- Ocular pressure (baseline if risk factors present, then annually)
- Psychiatric symptoms (ongoing assessment)
For Low-Dose Therapy (≤7.5 mg prednisone daily)
Standard care monitoring does NOT need extension except for 4:
- Osteoporosis prevention (follow national guidelines)
- Baseline assessment of ankle edema
- Baseline fasting blood glucose
- Baseline glaucoma risk factors
Mandatory Osteoporosis Prevention
For patients on prednisone >7.5 mg daily for >3 months, prescribe calcium and vitamin D supplementation (Level IA recommendation, 100% expert agreement) 1.
Bisphosphonate therapy should be initiated based on:
- Bone mineral density measurement
- Individual fracture risk factors
- Age and sex
- Duration of planned corticosteroid therapy
Gastrointestinal Protection
Patients on concurrent NSAIDs require gastroprotective therapy (proton pump inhibitors or H2-receptor antagonists) 1.
Dose Minimization Strategy
Keep corticosteroid dosage at the minimum effective level 1:
- Regularly reassess the need for continued therapy
- Attempt tapering when disease achieves remission or low activity
- Document specific reasons for continuing therapy at each visit
- Consider steroid-sparing agents for chronic use
A common pitfall: Adherence to osteoporosis prevention guidelines remains low in clinical practice despite strong evidence 3. Proactively prescribe calcium, vitamin D, and bisphosphonates rather than waiting for fractures to occur.
Economic Impact
Long-term corticosteroid use substantially increases healthcare costs 3:
- Low-dose users (<7.5 mg/day): $5,700 additional annual cost
- High-dose users (>15 mg/day): $29,000 additional annual cost
- Myocardial infarction complication: $26,472 per event
Special Populations
Immunocompromised patients require heightened vigilance for infectious complications, though specific dosing guidance remains limited due to systematic exclusion from landmark trials 5.
Pregnancy and breastfeeding require individualized risk-benefit assessment with involvement of obstetric specialists 6.
Critical Safety Points
- Adrenal insufficiency can occur with abrupt discontinuation or during physiologic stress (surgery, infection) even after stopping therapy
- Psychiatric effects can emerge at any dose but increase with higher doses and rapid administration 2
- Infection risk mandates vaccination updates before starting therapy when possible, though live vaccines are contraindicated during treatment
- Drug interactions are numerous; review all concomitant medications, particularly CYP3A4 inducers/inhibitors, anticoagulants, and antidiabetic agents